|

HB0036 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-PD-L1 and anti-TIGIT bifunctional molecule

Pipeline

Phase 1/2: 1

Top Sponsors

  • Shanghai Huaota Biopharmaceutical Co., Ltd.1

Indications

  • Advanced Solid Tumor1
  • NSCLC1
  • Cancer1

Lafayette, Indiana1 trial

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Horizon Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.